Oclacitinib

Oclacitinib
Oclacitinib.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Oclacitinib is a medication used in veterinary medicine primarily for the treatment of allergic dermatitis and pruritus in dogs. It is a selective Janus kinase (JAK) inhibitor, which helps to reduce inflammation and itchiness by interfering with the signaling pathways that lead to these symptoms.

Mechanism of Action

Oclacitinib works by inhibiting the activity of Janus kinase enzymes, specifically JAK1 and JAK3. These enzymes are involved in the signaling pathways of various cytokines that play a role in the inflammatory and pruritic processes. By blocking these pathways, oclacitinib reduces the production of inflammatory mediators and alleviates symptoms associated with allergic reactions.

Uses

Oclacitinib is primarily used to manage allergic dermatitis and pruritus in dogs. It is effective in reducing itching and inflammation associated with various allergic conditions, including atopic dermatitis.

Administration

Oclacitinib is administered orally, and the dosage is typically based on the weight of the dog. It is important to follow the veterinarian's prescription to ensure the effectiveness and safety of the treatment.

Side Effects

Common side effects of oclacitinib may include vomiting, diarrhea, and anorexia. In some cases, dogs may experience more serious side effects such as immunosuppression, which can increase the risk of infections.

Precautions

Oclacitinib should be used with caution in dogs with a history of neoplasia or immunosuppression. It is not recommended for use in dogs less than 12 months of age or in breeding, pregnant, or lactating dogs.

Related pages

• Allergic dermatitis
• Pruritus
• Janus kinase
• Cytokine

• 
  Oclacitinib